MTOR and diffuse large B-cell lymphoma: This signaling cascade promotes therapeutic resistance via anti-apoptotic effects, unchecked cell division, and angiogenesis, contributing to R/R DLBCL aggressiveness.23 Clinically validated PI3K inhibitors and dual PI3K/mTOR antagonists show promising effects in molecularly defined subsets, bringing new treatment options for R/R DLBCL patients.24